chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Arthus reactions, arm was red, swollen, hot to the touch, hard, itchy, the size of a softball for two weeks, lethargic, low grade fever.
Received flu vaccine on 10-26-06. First time ever receiving vaccine. Diarrhea on 10-27-06. 10-28-06 developed rash on face and trunk, felt lightheaded and dizzy. Treated in ED with Benadryl. 10-29-06 Rechecked in ED.  Rash gone.  Very sleep from Benadryl.
Case was vaccinated and boosted for Covid, yet was hospitalized for Covid 3 months later.  Hospitalized at:   Hospital .  Pneumonia due to COVID-19 virus Assessment & Plan Patient admitted with COVID-19 pneumonia, he received 5 days of dexamethasone on Remdesivir IV with excellent response to the treatment.   He is back to baseline with 4 L of O2 by nasal cannula. Baseline 3 to 4 L of O2 by nasal cannula   The plan moving forward will be for him to remain on dexamethasone 6 mg 1 tablet p.o. daily for 5 days and then dexamethasone 3 mg p.o. daily for 5 more days.
Inmate seen in health services with complaint of left ear pain extending into left cheek and  around his mouth. He has some drooping of the left side of his mouth and he is not able to  blink or close his left eye. He noticed symptoms on 1-23-2021, the Saturday after getting the COVID 19 vaccine on 1-21-2021 (Thursday). Had some trouble swallowing liquids without  having them dribble out the left side of his mouth and he says that he is not able to chew on the left side without biting his tongue. Says that his left ear is causing him a great deal of  pain.
This spontaneous report as received from a health care worker and follow up information received from a licensed practitioner nurse refers to a 13 year old female patient. On an unknown date the patient was vaccinated with a dose of (Merck) VARIVAX (lot#, dose and route was not reported). On an unknown date following vaccination of (Merck) VARIVAX the patient developed around 30 chicken pocks. And the patient was not pregnant. It was not known if the patient sought medical attention. The outcome of event was reported as not recovered/not resolved. Additional information is not expected.
armpit on the arm I received the shot is swollen; armpit on the arm I received the shot is sore; was running 100 degree temp; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 14-Jun-2021 and was forwarded to Moderna on 14-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (armpit on the arm I received the shot is swollen), AXILLARY PAIN (armpit on the arm I received the shot is sore) and PYREXIA (was running 100 degree temp) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SWELLING (armpit on the arm I received the shot is swollen), AXILLARY PAIN (armpit on the arm I received the shot is sore) and PYREXIA (was running 100 degree temp). At the time of the report, SWELLING (armpit on the arm I received the shot is swollen), AXILLARY PAIN (armpit on the arm I received the shot is sore) and PYREXIA (was running 100 degree temp) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided by the reporter.  Treatment information was not provided.
metallic taste No Trement Evaluated by allergist 1/14/21 - Reaction not IgE mediated. 2nd Dose without extended observation reommended Received 2nd dose 1/14/21 3 adverse reaction
Information has been received from a registered nurse concerning a female who on 03-FEB-2007 was vaccinated with Gardasil. In 2007 the patient experienced mononucleosis. The patient's mononucleosis persisted. Additional information has been requested.
C/o dizziness, redness/rash developing on chest and both forearms, flushing. B/P changes post 10 minutes of Moderna Booster dose
Has a severe headache 10 days post injection, photosensitivity, loss of vision. Has history of migraines, but hasn't had an event in 4 years until post vaccine.
Received COVID-19 vaccine booster dose prior to age 18. Patient is currently only experiencing soreness at the vaccine administration site.
had severely swollen tongue; had severely swollen eyes; had severely swollen palate; ran a fever for a week; Initial information received on 20-Oct-2021 regarding an unsolicited valid Social Media non-serious case from a consumer/non-health care professional.  This case involves a patient (unknown age and gender) who had severely swollen tongue (swollen tongue), swelling of eyes (eye swelling),swelling of palate (palatal swelling) and ran a fever for a week (pyrexia) after receiving INFLUENZA VACCINE.  The patient's medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.  It was unknown if the patient had any medical history, concomitant disease or risk factor.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiration date not reported) via unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date the patient developed a non-serious swollen tongue (swollen tongue), swelling of eyes (eye swelling), swelling of palate (palatal swelling) and ran a fever for a week (pyrexia) (unknown latency) following the administration of INFLUENZA VACCINE.  It was unknown if the patient experienced any additional symptoms/events  No laboratory data reported.  It was reported "Flu Shot Fridays Last year after the flu shot I had severely swollen eyes, tongue, and palate and ran a fever for a week. A week of my life I can not get back. Never again for a shot that is 17-50% effective."  It was not reported if the patient received a corrective treatment.  At time of reporting, the outcome was unknown for the reported events.  There will be no information on the batch number for this case.
7/21/04: pt received Dtap and IPV right arm 7/19/04. That night pt started fever of 101 degrees. Arm injection sites started swelling 7/20/04. Painful to touch. Instructed to apply cold compresses. Take Benadryl OTC and Tylenol for fever. 7/21/04: 1500 Pt's mother called.  Swelling worsened. Streaking. Very hot to touch. To be seen by physician. 7/21/04: Diagnosis: cellulitis to right deltoid. Treatment Cephalexin 250mg/5ml 1 tsp qid po x 10days. To continue Benadryl and ice. To follow up next week or sooner if need be.
Extra dose administered; fever; This spontaneous case was reported by a consumer and describes the occurrence of EXTRA DOSE ADMINISTERED (Extra dose administered) and PYREXIA (fever) in an 82-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013L20A, 031M20A and 014F21A) for COVID-19 vaccination.     "No medical history was provided by the reporter.".  Concomitant products included BUPROPION HYDROCHLORIDE (WELLBUTRIN) and FENOFIBRATE for an unknown indication.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Sep-2021, the patient experienced EXTRA DOSE ADMINISTERED (Extra dose administered) and PYREXIA (fever). At the time of the report, EXTRA DOSE ADMINISTERED (Extra dose administered) outcome was unknown and PYREXIA (fever) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were reported i.e., blood pressure medication No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 13-Oct-2021: FU email includes NNI.
Diarrhea problems; Fatigue/in bed for the day just from fatigue; More dramatic reaction; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (More dramatic reaction), DIARRHOEA (Diarrhea problems) and FATIGUE (Fatigue/in bed for the day just from fatigue) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 061E21A, 026L20A and 026L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Oct-2021, the patient experienced VACCINATION COMPLICATION (More dramatic reaction) and FATIGUE (Fatigue/in bed for the day just from fatigue). On an unknown date, the patient experienced DIARRHOEA (Diarrhea problems). At the time of the report, VACCINATION COMPLICATION (More dramatic reaction), DIARRHOEA (Diarrhea problems) and FATIGUE (Fatigue/in bed for the day just from fatigue) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant information was not provided.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-398465 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-398465:MOD21-167449,MOD21-167810 (Husbands case)
This spontaneous report received from a patient concerned a 42 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included hypertension, and other pre-existing medical conditions included the patient had no known drug allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808609, and expiry: UNKNOWN) dose was not reported, administered on 11-APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On 11-APR-2021, the subject experienced dizziness. On 11-APR-2021, the subject experienced body aching. On 11-APR-2021, the subject experienced chills. On 11-APR-2021, the subject experienced headache. On 11-APR-2021, the subject experienced fever. On 11-APR-2021, the subject experienced nausea. On 11-APR-2021, the subject experienced pain at injection site.  Laboratory data included: Body temperature (NR: not provided) 101.2 F. On 12-APR-2021, Laboratory data included: Body temperature (NR: not provided) 99.9 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from fever, and pain at injection site, and had not recovered from dizziness, headache, body aching, chills, and nausea. This report was non-serious.
Information has been received from a physician concerning a 30 month old male patient who was vaccinated with one dose of VARIVAX (Merck) when he was 1 year old in approximately August 2009. Sometime in past two weeks in approximately January 2011 the patient developed shingles. Patient developed the rash on right thigh where the VARIVAX (Merck) was administered. The patient sought unspecified medical attention. No treatment was given. At the time of the report, the patient's outcome was unknown. Additional information has been requested.
Fever. Chills body ache. Chest tightness. Nonproductive cough. Runny nose. Neck swollen. Tired
Headache; Fever (99); Tired; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A non-pregnant female patient of unspecified age received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8839) via an unspecified route of administration in the left arm on an unknown date as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS), gastritis and high blood pressure ("Hi" BP). The patient had known allergies to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously took hydrocodone bitartrate; paracetamol (VICODIN) and sulfur (MANUFACTURER UNKNOWN); both taken for unknown indications and experienced drug allergy. On 30Sep2021, the patient had headache, fever (99), was tired and was feeling unwell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 30Sep2021, the patient underwent body temperature test and the result was 99 (unspecified units). Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headache, fever (99), tired and feeling unwell was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
nausea & fatigue-onset noc of vax 22APR98;persisting x 3wk;no tx;
Chills 1:00am 5-7-21 until 2am Saturday 5-8-21 Extreme tiredness 6am 5-7 until 10pm Saturday 5-8 Moderate headache 1100 am 5-7 until 9am Saturday 5-8 Muscle aches 100 am 5-7 until 10pm 5-7 Moderate sore arm 7pm 5-7 until ongoing  I had Covid with moderate symptoms April 2020
This spontaneous report was received from a nurse referring to a patient of unknown age and gender. Patient's concurrent conditions, medical history and concomitant medications were not provided. On 13-DEC-2021, the patient was vaccinated orally with improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) 2 milliliter, lot # 1821791, expiration date: 26-JUL-2022, for prophylaxis. Rotavirus vaccine, live, oral, pentavalent (ROTATEQ) was improperly stored for 3 hours and 15 minutes in 9 degree Celsius (product storage error). There was no any previous temperature excursion.
About a week after the vaccine, I woke up in the middle of the night with severe dizziness.  I almost fell over when i tried to walk to the bathroom.  The dizziness has lasted this week.  On top of that, I have experienced shortness of breath the past few days.  I am currently having both the dizziness and SOB and hoping it will end soon.
Vaccination was given to a 17-year-old when Janssen is for 18 or over.  No adverse effects were seen.
marked erythema, induration & edema of arm vax given; swollen to >50% of normal size; pain; dec ROM in elbow; erythema edema circumferential from inject site to 12 cm above wrist;
local rxn in rt leg;red, hard lump, size of dime;no fever;very fussy 24hr p/vax;call to MD given APAP;seen in MD office;
Patient felt dizzy and fainted for a few seconds in the chair after getting the immunization. He complained of feeling dizzy, nauseous, sweating, and tingling pain. The patient was monitored in the waiting room and was asked to lie down and drink some water until his condition improved. He did not want us to call for help. After 15 to 20 minutes his condition improved and he walked out of the pharmacy.
This spontaneous report as received from a nurse refers to a patient of unknown age. In approximately June 2012, within the last 6 months, the patient was vaccinated with a dose of ZOSTAVAX, subcutaneously. No other co-suspects were reported. No concomitant medications were reported. The nurse mentioned the unspecified patient had experienced cellulitis after receiving ZOSTAVAX. The nurse stated that the unspecified patient did see an unspecified doctor for treatment of the cellulitis. The nurse stated that it was within the last 6 months that the ZOSTAVAX was given and cellulitis had occurred. The nurse was unable to provide specific dates. The nurse stated that the vaccine was administered at the clinic and the nurse was not involved in any follow up. At the time of the report, the outcome of cellulitis was unknown. This is one of several reports received from same reporter (other case # 1301USA000020). Additional information has been requested.
12/10/2021 1st Seizure - Fall at home alone - 2 nights in hospital - No Covid - Chills left side face and body. Wore Heart Monitor for 19 days. 05/19/2022 Hospital follow up. Tests - No Covid 07/10/2022 Home Seizure - 2 nights in hospital. No Covid -Weakness, parenthesis of skin, mild cognitive impairment, liver elevated transaminase levels, abnormalities of gait and mobility.  11/01/2022 Suspected seizure - 1 night in hospital. No Covid. Dementia, memory lapses, elevated liver, increased CK.  01/12/2023 Felt bad, stomach issue - 1 night in hospital - No Covid.  Diarrhea, elevated liver, chest pain, left arm tingling and pain, weight loss, dementia, hepatomegaly, increased anion gap.
Fatigue; This is a spontaneous report from a contactable consumer. A female patient of unknown age received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history was not reported. It was unknown whether the patient received any concomitant medications. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown whether the patient received any other vaccines within four weeks prior to the vaccination. On an unknown date the patient experienced fatigue. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether therapeutic measures were taken as a result of the event. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the event fatigue was recovered on an unknown date.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Adverse reaction; This case was reported by a nurse and described the occurrence of adverse reaction in a patient who received Flu Seasonal QIV Quebec (FluLaval Quadrivalent) for prophylaxis.   On an unknown date, the patient received FluLaval Quadrivalent at an unknown dose. On an unknown date, unknown after receiving FluLaval Quadrivalent, the patient experienced adverse reaction. On an unknown date, the outcome of the adverse reaction was unknown.   It was unknown if the reporter considered the adverse reaction to be related to FluLaval Quadrivalent.  Additional details were provided as follows: The age at vaccination was not reported. It was reported that, there was Flu immunization where the patient experienced flu adverse reaction. This is 1 of the 10 cases reported by the same reporter.
Extreme soreness/pain at injection site intermittently for at least 11 hrs post dose; Hard to lift arm up.; This is a spontaneous report from a non-contactable consumer (patient).   A 42-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: solution for injection, Lot number were not provided, Expiration date were not provided), via an unspecified route of administration on administered in arm left on 17Feb2021 at 13:30 (at the age of 42-years-old) as dose number unknown, single for covid-19 immunisation. Medical history included Obesity. Concomitant medications included escitalopram oxalate (LEXAPRO) taken for an unspecified indication, start and stop date were not reported. On an17Feb2021 at 17:00, the patient experienced extreme soreness/pain at injection site intermittently for at least 11 hrs post dose and hard to lift arm up. The patient not received treatment. The outcome of the events was not recovered.   No follow-up attempts are Possible. Information on Lot/batch number cannot be obtained. No further information is expected.
at site of injection arm was swollen, hot to touch, and red round circle about 1 inch diameter around injection site
Onset moderate/severe shingles left (L) 2 distribution approximately 5 hrs after vaccines.
massive headache; sick; tired; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (159558). The reporter is the parent.  A female patient received bnt162b2 (BNT162B2), administration date 02Aug2021 (Batch/Lot number: unknown) as dose 1, single and administration date 24Aug2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious) with onset Aug2021, outcome "recovering", described as "massive headache"; ILLNESS (non-serious) with onset Aug2021, outcome "recovering", described as "sick"; FATIGUE (non-serious) with onset Aug2021, outcome "recovering", described as "tired".  Additional information: Reporter mentioned that her daughter got her vaccines at the same time as the reporter. Said her daughter did okay, she was sick and tired, but she did okay. Attempted to gather more information from the reporter about her daughter's experience with the vaccines. Reporter stated that her daughter was sick, tired, had a massive headache. The second vaccine for her was the worst. Reporter stated that her daughter got better.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
adm w/flu-like sx flu shot 9 days earlier;pt w/underlying COPD went on to devel pneumonia & renal failure & resp failure, died 5NOV;
Vertigo within 15 minutes, nausea. Subsided quickly. Within the hour, itchy, swollen throat, flushed, very intense vertigo, shortness of breath.  Visited Emergency Room (04/06/2021), treatment was IV fluids, and Benadryl. Told to take Benadryl to within 24 hours, and symptoms did subside. After 24 hours, body aches and chills.
Site: Itching at Injection Site-Medium, Site: Redness at Injection Site-Medium, Systemic: Allergic: Itch Generalized-Medium, Systemic: Allergic: Rash Generalized-Medium
Moderna COVID-19 Vaccine EUA.  During the early hours of Thursday, 2/18 I awoke and experienced mild pain at the injection site.  This pain was very similar to that encountered immediately after the initial injection on 2/8.  By the evening of 2/18, a redness developed that became warm to the touch.  As of noon on 2/19 it has begun to itch.  The area of redness is approximately 4 square inches and roughly oval in shape.  None of these aftereffects have had an impact on movement or other normal activities using this arm.  I have experienced no other symptoms or problems except  as described at the site of the injection..